Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betahistine prolonged-release versus immediate-release versus placebo in adults with Meniere's disease
2020-005246-42Phase 3Active
- Sponsor
- Intas Pharmaceuticals
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of betahistine in Meniere Disease (3 arms), sponsored by Intas Pharmaceuticals. Primary endpoint: Percentage of significant responders. Started Oct 2021; status: active.
02
Drugs
betahistine
03
Conditions
Meniere Disease
Beyond the preview
Go deeper on 2020-005246-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005246-42.